Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12913966 | 0.83 | THRB (0.31) | — | |
| SCHEMBL31616916 | 0.81 | TSHR (0.32) | — | |
| SCHEMBL25695593 | 0.81 | THRB (0.31) | — | |
| SCHEMBL9148991 | 0.79 | CYP2D6 (0.50) | CYP2D6 | |
| Hydrochloric Acid SCHEMBL5595429 | 0.79 | TSHR (0.31) | — | |
| SCHEMBL24294598 | 0.77 | CYP2D6 (0.47) | CYP2D6 | |
| SCHEMBL12638432 | 0.74 | CYP2D6 (0.56) | CYP2D6 | |
| SCHEMBL23110419 | 0.73 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL4745166 | 0.72 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL22848071 | 0.71 | CA12 (0.52) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423048-B2 | Compounds for treating fundic disaccomodation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7081453-B2 | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | VAN EMELEN KRISTOF | 2006-06-29 | — | — | US | disclosed |
| EP-1296987-B1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-07 | — | — | EP | disclosed |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | JANSSEN-CILAG S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | CNR2, CNR1, CBR1 | CYP2D6 243/4885LOX 926/4885LOXL3 3074/4885 |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | ALK, ADORA1, CHRM2 | CYP2D6 558/4885LOX 1117/4885LOXL3 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.